Active substance
Results for the substance velaglucerase alfa
1 result
About this active substance
Velaglucerase alfa is a medication used for the treatment of type 1 Gaucher disease, a rare genetic disorder caused by a deficiency of the enzyme glucocerebrosidase. This deficiency leads to the accumulation of glucocerebroside in cells, affecting the function of organs such as the spleen, liver, and bone marrow. Velaglucerase alfa is a recombinant form of the glucocerebrosidase enzyme, which helps break down and remove glucocerebroside from cells.
The medication is administered intravenously, usually once every two weeks, and treatment requires regular monitoring to assess efficacy and safety.
Common side effects include injection site reactions, headaches, fatigue, and fever. In rare cases, severe adverse reactions such as allergic reactions or liver function impairment may occur.
Velaglucerase alfa represents an important therapeutic option for patients with type 1 Gaucher disease, helping to reduce symptoms and improve their quality of life.
The medication is administered intravenously, usually once every two weeks, and treatment requires regular monitoring to assess efficacy and safety.
Common side effects include injection site reactions, headaches, fatigue, and fever. In rare cases, severe adverse reactions such as allergic reactions or liver function impairment may occur.
Velaglucerase alfa represents an important therapeutic option for patients with type 1 Gaucher disease, helping to reduce symptoms and improve their quality of life.